Our Latest Data

International Conference on Antiviral Research (ICAR)

Las Vegas, NV | March 2025

• NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in Subjects not at Risk for Influenza Complications
• Real World Data-Based Modeling of Seasonal Influenza Variations to Support Clinical Dose Selection of CD388, A Novel Antiviral in Development for Prevention of Seasonal and Pandemic Influenza

IDWeek

Los Angeles, CA | October 2024

• CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model
• Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza [Poster] [Rapid Fire]

OPTIONS XII for the Control of Influenza

Brisbane, Australia | September 2024

• Safety Data from Phase 1 and Phase 2a Studies of CD388, a Drug Fc-conjugate for Seasonal Pan-Influenza Prophylaxis
• Pharmacokinetics and Safety of CD388 Following Subcutaneous Administration in Healthy Japanese Participants

ASM MICROBE

Atlanta, GA | June 2024

• Comparison of Different Allometric Scaling Approaches to Project Human Pharmacokinetics (PK) of CD388, a Novel Drug-Fc Conjugate, in Development for Influenza Prevention

Manuscript

• CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase bioRxiv | June 2024

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Barcelona, Spain | April 2024

• Prophylactic efficacy of CD388, a novel drug-Fc conjugate (DFC), in an influenza A/H3N2 human challenge model
• CD388, a drug-Fc conjugate, shows long half-life in early clinical studies

American Association for Cancer Research (AACR) Annual Meeting

San Diego, CA | April 2024

• Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model
• CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway
• CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
• CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization

ESMO Immuno-Oncology (IO) Annual Congress

Geneva, Switzerland | December 2023

• Discovery of a Novel, Dual CD73 & PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer [Poster] [Abstract]
• Discovery of CBO421, a First-in-Class Drug Fc-Conjugate (DFC), Targeting CD73 in Cancer [Poster] [Abstract]

Society for Immunotherapy of Cancer (SITC)

San Diego, CA | November 2023

• Discovery of CBO421, a First-in-Class Drug Fc-conjugate (DFC), Targeting CD73 in Cancer [Poster] [Abstract]

IDWeek

Boston, MA | October 2023

• Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), is Driven by the Small Molecule Neuraminidase Inhibitor (NAI)
• In Vivo Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), Against Seasonal Subtypes of Influenza in Prophylaxis in Immune Competent Mice, and in a Severe Immunodeficient (SCID) Mouse Model
• Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza [2514]

Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit

Boston, MA | June 2023

• Cidara Drug-Fc-Conjugates (DFCs): A New Approach to Treatment of Cancer

International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)

Seattle, WA | May 2023

• CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates Potent, Universal Activity Against Influenza A and B
• CD388 Demonstrates a High Barrier to Resistance and Retains Potent Activity Against NAI Influenza A and B

ESMO Targeted Anticancer Therapies

Paris, France | March 2023

• Discovery of CBO-212, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer

ESWI

Keynote Lecture | December 2020

• Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak^® Influenza Antiviral Conjugates (AVCs)

ESWI

VIRTUAL | December 2020

• In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI) [139]
• Efficacy of CD377, a Novel Antiviral Fc-Conjugate, by Multiple Dosing Routes Against Influenza A (H1N1), and Activity Against Oseltamivir-Resistant Isolates in Lethal Mouse Models [159]
• Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains [269]

IDWeek

VIRTUAL | October 2020

• Efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models [159]
• CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models [162]
• Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models [1276]
• New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single [1283]

ECCMID

Abstract Book | April 2020

• Preclinical Efficacy, Pharmacokinetics, and Safety of CD377, a Novel Antiviral Fc-Conjugate Against Influenza [Abstract 5126]
• CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Superior Reduction of Viral Burden and Cytokine Levels Compared to Oseltamivir in a Lethal Mouse Model of Influenza A (H1N1) Infection [Abstract 8839]
• Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Seasonal Influenza in Lethal Mouse Models [Abstract 5793]
• Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Influenza A (H1N1) in a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID) [Abstract 6009]
• CD377, a Novel Antiviral Fc-Conjugate, Demonstrates a Lower Resistance Potential than Baloxavir and Oseltamivir against Pandemic Influenza A/H1N1 [Abstract 5707]
• CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Potent Broad-Spectrum Activity in Multiple in vitro Assays Against Influenza A and B [Abstract 8832]
• Fc-Mediated Fcγ Receptor Engagement of CD377, a Novel Antiviral Fc-Conjugate, Translates Into Potent ADCP and ADCC Activity [Abstract 8820]

Manuscript

• Antivirals Targeting the Neuraminidase Cold Spring Harb Perspect Med | March 2020

IDWeek

Washington, D.C. | October 2019

• Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria) [689]

Options X

Singapore | August 2019

• Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, against Influenza A (H1N1) In a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID) [11760]
• Preclinical Efficacy, Pharmacokinetics, and Safety of CB-012, A Novel Antiviral Fc-Conjugate against Influenza [10973]
• Novel Antiviral Fc-Conjugate CB-012 Demonstrates Potent Activity in Cytopathic Effect (CPE) and Viral Growth Inhibition Assays against Influenza A and B Strains [10974]
• Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, in Lethal Mouse Models of Oseltamivir-Sensitive and -Resistant Influenza A H1N1 and H3N2 Isolates [10979]
• Fc-Mediated Effector Function Contributes to Potency of Novel Antiviral Fc-Conjugate CB-012 [11094]

ASM Microbe

San Francisco, CA | June 2019

• CB-012 – A Novel Antiviral-Fc Conjugate for Treatment and Prevention of Influenza Virus [SUNDAY – HMB-385]

ECCMID

Amsterdam | April 2019

• Cloudbreak: A Novel Approach for the Treatment and Prevention of Influenza Virus [O0818]